Sino Biopharmaceutical's (HKG:1177) co-developed penpulimab injection secured marketing approval from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.

The drug is indicated either in combination with cisplatin or carboplatin and gemcitabine, or as a single agent, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.